Prevail Therapeutics (NASDAQ:PRVL) Given Outperform Rating at Wedbush

Prevail Therapeutics (NASDAQ:PRVL)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a research note issued on Wednesday, 24/7 WallStreet reports.

PRVL has been the subject of several other research reports. Bank of America began coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued a “buy” rating and a $15.00 target price for the company. Morgan Stanley began coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, Cowen began coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued an “outperform” rating for the company.

NASDAQ PRVL traded up $0.33 during trading hours on Wednesday, hitting $11.10. The company had a trading volume of 700 shares, compared to its average volume of 43,503. Prevail Therapeutics has a 52 week low of $7.41 and a 52 week high of $16.90. The company’s 50 day moving average is $10.85. The company has a quick ratio of 26.94, a current ratio of 26.94 and a debt-to-equity ratio of 0.04.



Prevail Therapeutics (NASDAQ:PRVL) last issued its earnings results on Wednesday, August 14th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.66. Equities research analysts anticipate that Prevail Therapeutics will post -2.53 EPS for the current year.

In related news, Director Carl L. Gordon bought 882,352 shares of the business’s stock in a transaction on Monday, June 24th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $14,999,984.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

A number of hedge funds and other institutional investors have recently modified their holdings of PRVL. Orbimed Advisors LLC bought a new position in Prevail Therapeutics in the 2nd quarter worth about $182,457,000. EcoR1 Capital LLC bought a new stake in shares of Prevail Therapeutics during the 2nd quarter valued at about $31,582,000. Citadel Advisors LLC bought a new stake in shares of Prevail Therapeutics during the 2nd quarter valued at about $15,656,000. Boxer Capital LLC bought a new stake in shares of Prevail Therapeutics during the 2nd quarter valued at about $14,825,000. Finally, Omega Fund Management LLC bought a new stake in shares of Prevail Therapeutics during the 2nd quarter valued at about $8,830,000. Institutional investors and hedge funds own 77.49% of the company’s stock.

About Prevail Therapeutics

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Further Reading: Oversold

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.